Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Testosterone Levels in Benign Prostatic Hypertrophy and Prostate Cancer

Mearini L.a · Costantini E.a · Zucchi A.a · Mearini E.a · Bini V.b · Cottini E.a · Porena M.a

Author affiliations

Departments of aUrology and bInternal Medicine, University of Perugia, Perugia, Italy

Related Articles for ""

Urol Int 2008;80:134–140

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 08, 2006
Accepted: March 29, 2007
Published online: March 19, 2008
Issue release date: March 2008

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: Although hormones play fundamental roles in prostate growth, their clinical significance is not completely clear. In the present study we assessed whether serum hormone levels are markers of prostate disease. Patients and Methods: In 128 patients with benign prostatic hypertrophy or prostate cancer, testosterone, follicle-stimulating hormone, luteinizing hormone, and prolactin levels were correlated with disease. In patients with prostate cancer, the hormone levels were also correlated with prognostic factors. Predictive values were assessed for prostate-specific antigen and testosterone levels only, using multiple logistic regression analysis and receiver operating characteristic curves. Results: The testosterone concentrations were significantly lower in patients with prostate cancer than in those with benign prostatic hypertrophy and were also significantly lower in patients with advanced-stage disease than in patients with organ-confined disease. Testosterone appears to be an independent predictor of disease and enhances the predictive accuracy for benign prostatic hypertrophy and prostate cancer. Conclusions: This study supports experimental findings that prostate cancer is frequently associated with low testosterone concentrations. In the diagnostic workup for prostate cancer, associating prostate-specific antigen and testosterone levels may improve the predictive accuracy of prostate disease tests.

© 2008 S. Karger AG, Basel


References

  1. Vergho DC, Heine K, Wolff JM: The role of PSA in diagnosis of prostate cancer and its recurrence (in German). Pathologe 2005;26:473–478.
  2. Tricoli JV, Schoenfeldt M, Conley BA: Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943–3953.
  3. Singh AS, Chau CH, Price DK, Figg WD: Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract Urol 2005;2:101–107.
  4. Rubio J, Ramos D, López-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A: Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer: prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005;48:745–751.
  5. English HF, Kloszewski ED, Valentine E, Santen RJ: Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res 1986;46:839–844.
  6. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293.
  7. Rannikko S, Adlercreutz H: Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983;4:223–229.
  8. Kumar VL, Wadhwa SN, Kumar V, Farooq A: Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 1990;44:122–128.
  9. Schatzl G, Brossner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, Soregi S, Madersbacher S: Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55:397–402.
  10. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC: Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449–453.
  11. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670–1675.
  12. Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA: Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173:1935–1937.
  13. Zagars GK, Pollack A, von Eschenbach AC: Serum testosterone – a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997;49:327–334.
  14. Iversen P, Rasmussen F, Christensen IJ: Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994;157:41-47.
  15. Harper ME, Wilson DW, Jensen HM, Pierrepoint CG, Griffiths K: Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade. J Steroid Biochem 1987;27:521–524.
  16. Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002;89:710–713.
  17. Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, Huland H: Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol 2000;38:243–249.
  18. Porter AT, FACRO, Ben-Josef E: Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol 2001;6:131–138.
  19. Tian W, Osawa M, Horiuchi H, Tomita Y: Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Sci 2004;95:491–495.
  20. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS: Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847–853.
  21. Algarté-Génin M, Cussenot O, Costa P: Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur Urol 2004;46:285–295.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 08, 2006
Accepted: March 29, 2007
Published online: March 19, 2008
Issue release date: March 2008

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.